Article
Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.
Pain - 1 Dec 2009
Walter Carmen, Lötsch Jörn
Abstract excerpt
Regard of functional pharmacogenetic polymorphisms may further the success of pain therapy by adopting individualized approaches. The mu-opioid receptor gene (OPRM1) 118A>G polymorphism is a promising candidate for both opioid effects and pain because of both biological reasonability and apparent experimental and clinical evidence. We analyzed its importance for pain therapy using a meta-analytic approach to...
Topics
Join the communities discussing this publication.